Luca Guglielmo Pradotto, IRCCS Istituto Auxologico Italiano – Piancavallo (VB)

Condividi su
Data dell'evento: 25/06/2018
seminars_2018

Monday, 25th June – h. 15:00
Seminars Room, NICO

Luca Guglielmo Pradotto, MD, PhD
Division of Neurology and Neurorehabilitation
IRCCS Istituto Auxologico Italiano, Piancavallo (VB)

Pathogenic Mechanisms and New Molecular Therapies in Transthyretin-related Amyloidosis

Transthyretin (TTR)-related amyloidosis (aTTR) is the most common hereditary systemic amyloidosis. In aTTR polyneuropathy is the earliest manifestation of a multiorgan, life-threatening disease affecting also the heart, the gastrointestinal tract, the kidneys, the eyes. TTR amyloid formation is a multistep process in which TTR tetramer disassembling is the first and the rate-limiting step. Amyloidogenic TTR gene mutations reduce TTR tetramer stability leading to its dissociation into unfolded TTR species, monomers and dimers.

These partially unfolded TTR species spontaneously self-aggregate into oligomers, protofibrils and mature fibrils. Extracellular TTR aggregate deposition is tissue specific and followed by degenerative processes leading to programmed cell death. Despite aTTR is a severe life-threatening disease, aTTR is tractable and liver transplantation is the first-line specific treatment. Recently other new anti-amyloid therapies are available. A first molecular approach is to prevent TTR tetramer dissociation by specific stabilizers.

The stabilizers now available are thyroxine mimicker compounds which bind covalently the thyroxine binding pocket of TTR tetramer. Other innovative available medicines are siRNA which block the hepatic production of TTR. Future anti-amyloid approaches are to remove the amyloid deposits by monoclonal antibody anti serum amyloid P component or by doxycycline–taurodesoxycholic acid treatment, which were effective in transgenic mice.

Host: Alessandro Vercelli

Agenda

17 aprile 2019

From split-brains to emotional consciousness - A tribute to Joseph LeDoux

Wednesday 17th April 2019 – h 9.30
Accademia delle Scienze di Torino, Sala dei Mappamondi
Via Accademia delle Scienze 6, Torino

26 aprile 2019

NICO Progress Report - INN Open Neuroscience Forum 2019

I nostri giovani ricercatori aggiornano i colleghi sulle loro ricerche. Appuntamento ogni due venerdì.

Ricerca

Atassia: scoperto il difetto cellulare responsabile di una rara malattia neurologica

Un malfunzionamento dei mitocondri, le centrali energetiche delle cellule, causa lo sviluppo della SCA28, una forma ereditaria di atassia. Dopo 10 anni di studi e grazie al sostegno di Fondazione Telethon, la scoperta del team di ricerca guidato dai proff. Alfredo Brusco e Filippo Tempia dell’Università di Torino e NICO. Lo studio pubblicato sulla prestigiosa rivista Neurobiology of Disease.

4 dicembre 2018